BridgeBio Pharma (BBIO) Projected to Post Earnings on Tuesday

Key Points

• BridgeBio Pharma is set to report its Q2 2025 earnings on August 5th, with analysts predicting a loss of $0.50 per share and revenue of $98.46 million.
• The company recently reported a 44.8% decline in quarterly revenue year-over-year, with earnings of ($0.88) per share compared to market expectations.
• Despite recent struggles, analysts maintain an average rating of "Moderate Buy" for BridgeBio, with a target price of $61.50, based on 16 buy ratings.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) is projected to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 5th. Analysts expect BridgeBio Pharma to post earnings of ($0.50) per share and revenue of $98.46 million for the quarter.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.12. The company had revenue of $36.74 million during the quarter, compared to analysts' expectations of $57.14 million. BridgeBio Pharma's revenue for the quarter was down 44.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.20) EPS. On average, analysts expect BridgeBio Pharma to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BridgeBio Pharma Price Performance

BridgeBio Pharma stock traded down $0.70 during trading hours on Wednesday, reaching $45.62. The stock had a trading volume of 1,683,267 shares, compared to its average volume of 2,216,534. BridgeBio Pharma has a 52 week low of $21.72 and a 52 week high of $48.68. The company has a market cap of $8.66 billion, a price-to-earnings ratio of -12.92 and a beta of 1.15. The business's 50 day moving average price is $41.74 and its 200-day moving average price is $36.87.

Analysts Set New Price Targets

BBIO has been the topic of a number of recent analyst reports. Raymond James Financial began coverage on BridgeBio Pharma in a research report on Wednesday. They set an "outperform" rating and a $56.00 price target on the stock. Bank of America increased their price objective on shares of BridgeBio Pharma from $50.00 to $54.00 and gave the company a "buy" rating in a research report on Wednesday, June 25th. HC Wainwright raised their price target on shares of BridgeBio Pharma from $53.00 to $56.00 and gave the stock a "buy" rating in a report on Monday, June 9th. Wells Fargo & Company boosted their price target on BridgeBio Pharma from $67.00 to $76.00 and gave the company an "overweight" rating in a research note on Monday, June 30th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $95.00 target price on shares of BridgeBio Pharma in a report on Tuesday. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, BridgeBio Pharma has a consensus rating of "Moderate Buy" and a consensus price target of $61.18.

Insider Activity

In related news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $34.20, for a total transaction of $205,200,000.00. Following the completion of the sale, the insider directly owned 13,260,971 shares in the company, valued at approximately $453,525,208.20. The trade was a 31.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Andrew Lo sold 100,000 shares of BridgeBio Pharma stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $38.50, for a total transaction of $3,850,000.00. Following the sale, the director directly owned 105,583 shares in the company, valued at approximately $4,064,945.50. This trade represents a 48.64% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 9,851,181 shares of company stock worth $372,969,914. Company insiders own 18.20% of the company's stock.

Institutional Investors Weigh In On BridgeBio Pharma

An institutional investor recently bought a new position in BridgeBio Pharma stock. Jones Financial Companies Lllp bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 1,000 shares of the company's stock, valued at approximately $35,000. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.